![BioGaia, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/1d12ad0a-8185-425d-8445-1ba5281aa3a0.png)
Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
BioGaia
130,9 SEK +5,65%2 sijoittajaa seuraa yhtiötä
BioGaia is a biotechnology company. The company develops, markets and sells probiotic products. The products are mainly based on the bacterium Lactobacillus, which has probiotic effects. Today, the company's products are sold around the global market. Research and development are conducted via the company's external network of research institutions and clinics. The head office is located in Stockholm.
Liikevaihto
-
EBIT %
-
P/E -luku
36,16
Osinkotuotto %
-
Tavoitehinta
-
Suositus
-
Päivitetty
-
NASDAQ Stockholm
BIOG B
Päivän matalin / päivän korkein hinta
128 / 135,4
SEK
Markkina-arvo
13,22 mrd. SEK
Vaihto
35,85 milj. SEK
Vaihtomäärä, kappaletta
271 t.
Viimeisimmät videot
Pörssikalenteri
Osavuosikatsaus
23.07.2024
Osavuosikatsaus
22.10.2024
Suurimmat omistajatLähde: Millistream Market Data AB
Omistaja | Osuus | Ääniä |
---|---|---|
EQT | 11,1 % | 8,3 % |
Fjärde AP-fonden | 7,7 % | 5,8 % |
Inderes Premium
Tämä sisältö on vain Inderes Premium -käyttäjille.
NäytäKaikki sisältötyypit
![BioGaia, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/1d12ad0a-8185-425d-8445-1ba5281aa3a0.png)
BioGaia AB: Interim Management Statement January - June 2024
Annual General Meeting of BioGaia
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
![BioGaia, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/196bca62-f1be-492d-ae0d-e2aa03250d46.png)
BioGaia, Audiocast with teleconference, Q1, 2024
BioGaia AB: Interim Management Statement January - March 2024
Notice to attend the Annual General Meeting of BioGaia AB (publ)
BioGaia Annual and Sustainability Report 2023 published
![BioGaia, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/80dcd3f2-6039-493c-b556-73d7392b8300.png)
BioGaia, Audiocast with teleconference, Q4, 2023
BioGaia AB: Year-end report January - December 2023
![BioGaia, Audiocast with teleconference, Q3, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/3f7336b5-794a-4485-8f6f-90caae933d69.png)
BioGaia, Audiocast with teleconference, Q3, 2023
BioGaia AB: Interim report third quarter January - September 2023
BioGaia AB's Nomination Committee for the 2024 Annual General Meeting
BioGaia's results for the third quarter to exceed market expectations
Invitation to media and analyst briefing for BioGaia Q3 2023 report
Theresa Agnew commences her role as CEO of BioGaia
Introducing BioGaia Prodentis KIDS in Sweden
BioGaia and University of Gothenburg reach an important milestone towards next-generation probiotics
BioGaia appoints Theresa Agnew as new CEO
![BioGaia, Audiocast with teleconference, Q2, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/12f84f2e-e6c1-4944-a0c6-6847070fd7d3.png)